Movement is one of the most talked-about topics in lymphoedema and lipoedema, and one of the easiest to misread. A single word, exercise, can describe a trial in people who have not developed swelling, a package of care for established lymphoedema, or a daily activity a person values for its own sake. Those are three different questions, and the research answers them differently.
This article explains what was studied, in whom and with what limits. It does not offer an exercise plan, a dose, a programme or a progression rule, and it should not be used as one.
Editorial note: this article is educational and has not been medically reviewed. It explains how evidence is built and read. It does not diagnose, prescribe, set an activity level or promise an outcome. What is suitable for a particular person belongs with a qualified professional. New, rapidly changing or worrying swelling or skin changes, or fever or feeling unwell, need appropriate NHS or urgent-care advice, and breathing difficulty, chest pain or collapse needs emergency help.
A scope note first. This article stays within the sources reviewed in Chapter 5 of the Field Guide. It is not a survey of every exercise trial, and other studies may exist. Read original papers before drawing conclusions from any summary, including this one.
Three questions hidden inside the word exercise
Chapter 5 separates the ways movement can be studied. They are related, but they are not interchangeable.
- Prevention: does something done in people at risk change whether clinically detectable lymphoedema develops?
- Management: what is movement's place alongside other elements of care for established swelling?
- Function, participation and symptom experience: does a person feel and do things differently, whatever the volume measure shows?
A person may value confidence with movement, or being able to work and look after others, even when a limb measurement barely changes. A measured physical change does not automatically mean better function. Keeping the three questions apart is the first step in reading any claim.
Prevention: what the Cochrane review covers
Stuiver and colleagues (Cochrane Database of Systematic Reviews, 2015) reviewed human randomised trials of conservative interventions for preventing clinically detectable upper-limb lymphoedema in people at risk after breast-cancer therapy. Book 01 draws two things from it. There is a safety and function signal for exercise in the defined prevention trials. And there are real limits: the quality of the evidence was described as low or inconsistent, the outcomes varied and uncertainty remained.
The population is specific. These were people at risk of upper-limb lymphoedema after breast-cancer therapy, and the outcome was whether lymphoedema became clinically detectable. That does not describe people with established swelling, lymphoedema of the legs, lymphoedema from other causes or lipoedema. The review does not provide a dose, a programme, a progression rule or a prescription. Later human research needs the same checks for population, comparator, supervision, outcome and follow-up before anyone treats it as an instruction.
Management: movement as one part of a package
For established lymphoedema, the International Society of Lymphology 2020 consensus (Lymphology) presents management as a set of elements that can be combined around assessment, symptom control, skin integrity, movement, compression, education and self-management. That is a consensus of literature and practice. It reflects how care is often delivered and does not test movement by itself.
When several elements arrive together, the package can be sensible while the contribution of any one element, movement included, stays hard to isolate. Book 01 is careful here: a mention of movement in a package is not an instruction, and a study result is not a personal plan.
The NHS lymphoedema treatment page gives public orientation to broad management building blocks and to specialist or self-management context. Chapter 5 describes it as orientation, not an effect estimate. British Lymphology Society documents add professional and operational language, and Lymphoedema Support Network information adds patient-facing context. None of them is a trial of movement.
Lipoedema: a different evidence position
The 2024 S2k guideline (Faerber and colleagues) discusses conservative management questions in a field where terminology, criteria, outcomes and comparative evidence remain incomplete. Its strength is structured consensus and a visible account of evidence gaps. It is not an efficacy trial and does not supply a universal protocol.
Chapter 5 adds that conservative studies in lipoedema may bundle education, compression, movement, manual approaches and symptom support, then follow selected participants for different periods. When elements are bundled, a result cannot be assigned to movement alone.
The 2025 systematic review and meta-analysis of health-related quality of life in lipoedema (Günay, Talak and Demiroz, Phlebology) is relevant for a different reason. It reports effects across physical, pain, social, emotional and energy-related domains in adult women across several countries. The evidence was heterogeneous, mostly cross-sectional and often measured with generic instruments. It shows why outcomes beyond size matter when movement is studied. It does not show what movement does to those outcomes.
Outcomes: size, function and lived impact
The outcome a study picks decides what its result can say. Hidding and colleagues (Physical Therapy, 2016) reviewed measurement properties in lymphoedema and described heterogeneous evidence and population limits. A volume change under one method is not interchangeable with a change under another, a point the head-to-head work by Deltombe and colleagues (Lymphology, 2007) illustrates for a defined upper-limb cohort.
Movement research asks for outcomes that reach daily life. The Lymph-ICF questionnaire (Devoogdt and colleagues, Physical Therapy, 2011) was evaluated in an arm lymphoedema population and records functioning and disability. LYMPROM (Thomas and colleagues, PLOS ONE, 2025) was validated in UK and Wales adults and covers physical, social and emotional impact. These instruments belong to the populations and purposes in which they were tested. A questionnaire score is a record of experience in a set format, and it cannot say why that experience changed.
Follow-up, supervision, access and participation
A prevention trial that follows people for a short period answers a short-term question. Attrition changes who remains visible in the results. Supervised programmes in a specialist setting may not resemble what is available or practical elsewhere.
Chapter 5 lists access, cost, travel, time, body comfort and stigma as influences on both use and outcome. People may stay away from some activities because of pain, discomfort, fear of being judged or the cost of getting there. That is a reason to treat participation and burden as findings, not as a failure of the participant. It is also a reason to keep body-neutral language: size does not settle a diagnosis, and none of this research is a message about weight.
Safety reporting and the skin
Good studies report harms and practical burdens. Skin integrity and infection sit beside movement in the management literature, and NICE NG141 (cellulitis and erysipelas: antimicrobial prescribing) provides a named UK scope for infection and prescribing. Book 01 includes it for service context only. It does not diagnose lymphoedema or lipoedema, and this article gives no antibiotic or skin-care advice. A changing or worrying skin concern is a reason to seek the appropriate NHS or professional help for the situation, not to work it out from a research summary.
Questions to ask of a movement claim
- Is it about prevention, management or function? Which one did the study measure?
- Who was studied, and does that group match the claim being made?
- Was movement tested alone, or inside a package?
- What was the comparator, and what background care did both groups receive?
- Which outcome was primary: volume, pain, function or quality of life?
- How long were people followed, and who dropped out?
- Were harms and practical burdens reported?
- Does the source say it applies outside its own population?
What this evidence does not establish
- An exercise dose, programme, intensity or progression for any person.
- That a prevention signal in at-risk people applies to established lymphoedema or to lipoedema.
- That a change in volume means a change in pain, function or quality of life, or the reverse.
- A personal prognosis or a guaranteed outcome.
The honest summary is modest. Defined trials give a bounded signal in a bounded population, consensus documents describe how movement sits within care, and lipoedema evidence is still being assembled. For definitions, use the glossary; for how UK guidance and local services fit together, see the UK services context page.
Sources used
- Stuiver MM et al. Conservative interventions for preventing clinically detectable upper-limb lymphoedema in patients at risk after breast cancer therapy. Cochrane Database Syst Rev. 2015;Issue 2:CD009765. Cochrane systematic review. DOI.
- International Society of Lymphology. 2020 Consensus Document. Lymphology. 2020;53(1):3-19. Expert consensus. DOI.
- Faerber G et al. S2k guideline lipedema. J Dtsch Dermatol Ges. 2024;22(9):1303-1315. Guideline and structured consensus. DOI.
- Günay UB et al. Health-related quality of life among lipedema patients. Phlebology. 2025. Systematic review and meta-analysis. PubMed.
- Hidding JT et al. Measurement properties of instruments for measuring of lymphedema. Phys Ther. 2016;96(12):1965-1981. Systematic review. DOI.
- Deltombe T et al. Reliability and limits of agreement of circumferential, water displacement and optoelectronic volumetry. Lymphology. 2007;40:26-34. PubMed.
- Devoogdt N et al. Lymph-ICF. Phys Ther. 2011;91(6):944-957. Measure validation. DOI.
- Thomas M et al. LYMPROM. PLOS ONE. 2025;20(5):e0315314. Measure validation. DOI.
- NHS. Lymphoedema treatment. UK public information.
- NICE. NG141, Cellulitis and erysipelas: antimicrobial prescribing. UK infection and prescribing guidance, context only.
- British Lymphology Society operational documents and Lymphoedema Support Network patient information.
